Roche invests CHF190 million in Herceptin production site
This article was originally published in Scrip
Executive Summary
Roche is to pour CHF190 million ($185 million) into its production sites at Kaiseraugst, Switzerland and Mannheim, Germany to manufacture a device to allow patients to self-administer biological cancer medicines.